These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22088356)

  • 1. [Efficacy of intravitreal injections of ranibizumab compared to visudyne phototherapy in myopic choroidal neovascularization associated with high myopia].
    Dethorey G; Leveziel N; Lalloum F; Forte R; Guigui B; Querques G; Glacet-Bernard A; Soubrane G; Souied HÉ
    J Fr Ophtalmol; 2012 Feb; 35(2):106-12. PubMed ID: 22088356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intravitreal bevacizumab injections versus verteporferin photodynamic therapy for macular choroidal neovascularization in high myopia: 24-month follow-up].
    El Matri L; Chebil A; Bouraoui R; Kort F; Bouladi M; Basaraih S
    J Fr Ophtalmol; 2013 Jan; 36(1):29-34. PubMed ID: 23238073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
    Yoon JU; Byun YJ; Koh HJ
    Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
    Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
    Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
    Wolf S; Balciuniene VJ; Laganovska G; Menchini U; Ohno-Matsui K; Sharma T; Wong TY; Silva R; Pilz S; Gekkieva M;
    Ophthalmology; 2014 Mar; 121(3):682-92.e2. PubMed ID: 24326106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization.
    Wu TT; Kung YH
    J Ocul Pharmacol Ther; 2014 Dec; 30(10):837-41. PubMed ID: 25162313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH; Wu TT; Huang YH
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
    Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M
    Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
    Shi X; Wei W; Zhang C
    Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
    Husain D; Kim I; Gauthier D; Lane AM; Tsilimbaris MK; Ezra E; Connolly EJ; Michaud N; Gragoudas ES; O'Neill CA; Beyer JC; Miller JW
    Arch Ophthalmol; 2005 Apr; 123(4):509-16. PubMed ID: 15824225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
    Ladaique M; Dirani A; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
    Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
    Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD].
    Maier MM; Feucht N; Fiore B; Winkler von Mohrenfels C; Kook P; Fegert C; Lohmann C
    Klin Monbl Augenheilkd; 2009 Jun; 226(6):496-502. PubMed ID: 19507101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.
    Cionni DA; Lewis SA; Petersen MR; Foster RE; Riemann CD; Sisk RA; Hutchins RK; Miller DM
    Ophthalmology; 2012 Feb; 119(2):327-32. PubMed ID: 22133795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravitreal ranibizumab therapy for choroidal neovascularization secondary to pathological myopia].
    Lukács R; Sándor G; Resch M; Szabó A; Barcsay G; Ecsedy M; Szepessy Z; Nagy ZZ; Papp A
    Orv Hetil; 2017 Apr; 158(15):579-586. PubMed ID: 28393596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN; Tuomi L; Chung CY; Singh A;
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.